River Vision Development Corp., a company that develops a novel protein therapy for the treatment of Graves’ Orbitopathy (GO), completed a $17m Series A financing.
The company intends to use the capital to develop its protein therapy, RV 001, for the treatment of Graves’ Orbitopathy (GO), which is a condition afflicting a proportion of Graves’ Disease patients.
In conjunction with the financing, Brian M. Gallagher, Jr., Ph.D. a partner at SR One and Johan Kördel, Ph.D. a senior partner at Lundbeckfonden have joined River Vision’s Board of Directors.
Led by Dave Madden, CEO, the company was founded by Narrow River Management, LP to develop RV001 for GO and other potential indications. It is managed under contract with Narrow River, which founds and provides leadership expertise for special purpose drug development companies.